Loading
A phase 1/2 trial of Cobolimab, Dostarlimab in melanoma and hodgkin lymphoma, run by GlaxoSmithKline, active and no longer recruiting.
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer is a phase 1/2 interventional study registered as NCT06521567 by GlaxoSmithKline, with 83 participants planned, started 2025-03-06 and due to reach its primary completion in 2026-10-13. Interventions recorded: Cobolimab, Dostarlimab. Conditions listed: Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM). No results are recorded here; the registry entry is the source.
Shares TIM-3 blockade, Cobolimab, GSK.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors.
Shares TIM-3 blockade, Cobolimab.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors.